The upcoming HRSA 340B rebate model pilot represents a fundamental shift from upfront drug discounts to a post-purchase rebate system. The AHA contends this forces hospitals to provide interest-free loans to drug manufacturers and will create significant new operational costs and cash flow challenges.
The discussion highlights how 340B savings are a critical lifeline for hospitals serving vulnerable communities. For example, Monument Health uses its $84 million in savings to offset over $123 million in uncompensated care and to directly fund services like neonatal care, behavioral health, and patient transportation that would otherwise be unsustainable.
Congress is showing increased interest in the 340B program's growth and is demanding more transparency in how savings are used. Opponents claim the program has grown too large, while the AHA argues this growth is a direct result of legislative expansions and, more importantly, soaring drug prices set by manufacturers.
Hospital leaders are urged to proactively engage with lawmakers and community stakeholders to demonstrate the program's value. By providing concrete examples and data on how 340B dollars are used—and putting a human face on the issue—hospitals can build a strong defense against legislative and regulatory threats.
A key battleground for the 340B program is at the state level, where drug companies are legally challenging hospitals' ability to use contract pharmacies. In response, states like South Dakota are passing protective legislation to ensure hospitals can continue these partnerships, which are vital for patient access in many communities.
Keep pulling the thread on 340B Drug Pricing Program.